Citius Pharmaceuticals (NASDAQ:CTXR) Earns Buy Rating from HC Wainwright

Citius Pharmaceuticals (NASDAQ:CTXR)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a report released on Tuesday,Benzinga reports. They presently have a $4.00 target price on the stock.

Separately, EF Hutton Acquisition Co. I upgraded shares of Citius Pharmaceuticals to a “strong-buy” rating in a research report on Monday, July 15th.

Citius Pharmaceuticals Stock Performance

Shares of CTXR stock opened at $0.45 on Tuesday. The stock’s 50-day moving average is $0.45 and its two-hundred day moving average is $0.61. Citius Pharmaceuticals has a 1 year low of $0.31 and a 1 year high of $1.07. The firm has a market cap of $81.18 million, a price-to-earnings ratio of -1.87 and a beta of 1.66.

Citius Pharmaceuticals (NASDAQ:CTXR) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.06) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.01). As a group, research analysts predict that Citius Pharmaceuticals will post -0.21 EPS for the current year.

Hedge Funds Weigh In On Citius Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in CTXR. BNP Paribas Financial Markets grew its stake in shares of Citius Pharmaceuticals by 88.5% in the 1st quarter. BNP Paribas Financial Markets now owns 69,615 shares of the company’s stock valued at $62,000 after purchasing an additional 32,686 shares during the last quarter. Vanguard Group Inc. grew its position in Citius Pharmaceuticals by 1.5% in the 1st quarter. Vanguard Group Inc. now owns 7,005,119 shares of the company’s stock valued at $6,286,000 after buying an additional 104,889 shares during the last quarter. Arkadios Wealth Advisors increased its stake in Citius Pharmaceuticals by 50.0% in the 2nd quarter. Arkadios Wealth Advisors now owns 150,000 shares of the company’s stock valued at $88,000 after buying an additional 50,000 shares during the period. Point72 DIFC Ltd purchased a new position in Citius Pharmaceuticals during the 2nd quarter worth $29,000. Finally, Cubist Systematic Strategies LLC purchased a new stake in shares of Citius Pharmaceuticals in the second quarter valued at about $69,000. Institutional investors and hedge funds own 16.88% of the company’s stock.

Citius Pharmaceuticals Company Profile

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.